We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




IFN‐γ Release Assay Helps Diagnose Hemophagocytic Lymphohistiocytosis

By LabMedica International staff writers
Posted on 14 Aug 2020
Hemophagocytic lymphohistiocytosis (HLH), either primary (pHLH, or Familiar, FHL) or secondary is a life‐threatening hyper‐inflammatory syndrome, characterized by massive and uncontrolled activation of macrophages and T cells, causing fever, cytopenia and liver dysfunction with coagulopathy.

The rarity of the HLH disease, along with its pleomorphic clinical presentation that mimics a number of different conditions (from severe infections to malignancies), makes the diagnosis challenging. More...
Hemophagocytosis on bone morrow biopsy is the only histomorphological criterion, but, in itself, it is neither specific nor sensitive.

Hematologists at the Bambino Gesù Children's Hospital (Rome, Italy) diagnosed and treated 13 children with pHLH at the hospital from August 2014 to April 2020. During the diagnostic evaluation, all patients were tested for tuberculosis (TB) exposure through QuantiFERON‐TB Gold (QFT‐G, Qiagen, Hilden, Germany). The QuantiFERON test is an IFN‐γ release assay (IGRA), which measures IFN‐γ release in response to tuberculosis (TB)‐specific antigens. After centrifugation, plasma was harvested and enzyme‐linked immunosorbent assay (ELISA) tests were run.

The scientists reported that results obtained from the HLH group (all tests were reported as ‘Indeterminate’ because of high levels of IFN‐γ in the NIL Tube) were compared with three other groups of pediatric patients (matched for gender) with an available QFT‐G. These groups were: 13 children hospitalized for acute leukemia (AL) at time of diagnosis, 13 because of sepsis and 13 healthy controls (HC). The median (range) IFN‐γ levels at diagnosis/before starting treatment in the HLH group was 2.49 IU/mL (0.12–15.11) , significantly higher than those found in the AL, sepsis and HC groups, in which the median (range) value was 0.04 IU/mL (0.02–0.11) 0.07 (IU/mL 0.03–0.15) and 0.036 IU/mL (0.015–0.077) , respectively. A cut‐off value of 0.12 IU/mL had a sensitivity of 100% and a specificity of 97.3%.

The authors concluded that QFT‐G Plus, a diffuse and standardized blood test, in association with HLH‐04 criteria could support clinicians in determining a diagnosis of pHLH with high sensitivity and specificity. Although other interferonopathies, genetic or acquired, such as systemic lupus erythematosus and juvenile dermatomyositis, could impair the specificity of the analysis, this simple diagnostic test could really support pediatricians in peripheral hospitals. The study was published on July 26, 2020 in the British Journal of Haematology.

Related Links:

Bambino Gesù Children's Hospital
Qiagen

Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Host Response Immunoassay Test
MeMed BV
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.